PDCD1 and neoplasm: By increasing FC/PD-1-CTL penetration in tumor tissue and boosting the systemic immunoactivation levels of cytokines, hEnd-Apt/CD3-Lipo-modified FC/PD-1-CTLs showed improved tumor-fighting capacity and survival rates in vivo in tumor xenograft animal studies [85].